With the increase in large multimodal cohorts and high‐throughput technologies, the
potential for discovering novel biomarkers is no longer limited by data set size. Artificial …

Clinical trials in dementia with Lewy bodies: the evolving c... : Current Opinion in Neurology
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient …

Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration
could identify individuals at risk for cognitive decline in Alzheimer's disease (AD). In blood …

Background and objective Phosphorylated tau (p-tau) 217 has recently received attention
because it seems more reliable than other p-tau variants for identifying Alzheimer's disease …

Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations
with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p …

Polycystic ovary syndrome (PCOS) is the most common endocrine condition in women of
reproductive age, and several risk factors found in PCOS are associated with an increased …

INTRODUCTION Detection of Alzheimer's disease (AD) pathophysiology among individuals
with mild cognitive changes and those experiencing subjective cognitive decline (SCD) …

The deposition of highly phosphorylated and aggregated tau is a characteristic of
tauopathies, including Alzheimer's disease. It has long been known that different isoforms of …

Background Maximizing the efficiency to screen amyloid-positive individuals in
asymptomatic and non-demented aged population using blood-based biomarkers is …

Background LUMIPULSE G-automated immunoassays represent a widely used method for
the quantification of Alzheimer's disease (AD) biomarkers in the cerebrospinal fluid (CSF) …